Inflammation Phase Articles & Analysis
3 news found
By demonstrating significant clinical benefit together with a decrease in type 2 inflammation following IL-4 and IL-13 blockade with Dupixent, the Dupixent Phase 3 clinical program has established that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases for which ...
By demonstrating significant clinical benefit together with a decrease in type 2 inflammation following IL-4 and IL-13 blockade with Dupixent, the Dupixent Phase 3 clinical program has established that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases for which ...
Head of Global Development in Immunology and Inflammation at Sanofi. "This Phase 2a trial is the foundation of our clinical trial program with amlitelimab in atopic dermatitis. The forthcoming global Phase 2b trial will further evaluate the impact of amlitelimab when given subcutaneously in patients with moderate-to-severe atopic dermatitis. The ...